Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1S5CB)

• Drug Name: 2-methyl-5-HT Drug Info
• Synonyms: 2-methyl-5-hydroxytryptamine; 2-Me-5-HT; 2-methylserotonin
• Cross-matching ID:
  PubChem CID: 1574
  ChEBI ID: CHEBI:31085
  CAS Number: CAS 78263-90-8
  TTD Drug ID: DM1S5CB

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1B receptor (HTR1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[8]
Eletriptan	DMW649X	Migraine	8A80	Approved	[9]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[9]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[9]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[9]
Naratriptan	DMO50U2	Headache	8A80-8A84	Approved	[10]
Prolixin decanoate	DMMJ1IS	Schizophrenia	6A20	Approved	[9]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[11]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[12]
[N-methyl-3H(3)]AZ-10419369	DMSCV02	Mood disorder	6A60-6E23	Phase 1	[13]

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[14]
Eletriptan	DMW649X	Migraine	8A80	Approved	[9]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[9]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[9]
Sumatriptan	DMVYXR8	Cluster headache	8A81.0	Approved	[15]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[16]
Almogran	DM7I64Z	Migraine	8A80	Approved	[17]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[18]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[19]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[12]

Drug(s) Targeting 5-HT 6 receptor (HTR6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LU AE58054	DMWGRQD	Schizophrenia	6A20	Phase 3	[20]
SB-742457	DM6L4ZT	Alzheimer disease	8A20	Phase 3	[21]
AVN 211	DMVB4OS	Schizophrenia	6A20	Phase 2/3	[22]
SYN120	DMDF7XB	Parkinson disease	8A00.0	Phase 2	[23]
AVN 101	DMJFLBC	Alzheimer disease	8A20	Phase 2	[22]
SYN-120	DMPW0UL	Alzheimer disease	8A20	Phase 2	[24]
PF-05212377	DMPVQYR	Alzheimer disease	8A20	Phase 2	[25]
AVN 322	DMK2LGM	Cognitive impairment	6D71	Phase 2	[21]
SAM-531	DMHVJZ6	Alzheimer disease	8A20	Phase 2	[26]
SUVN-502	DMQD753	Alzheimer disease	8A20	Phase 2	[27]

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[28]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[29]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[30]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[31]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[32]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[33]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[34]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[34]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[34]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[34]

Drug(s) Targeting 5-HT 3B receptor (HTR3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[35]
SEROTONIN	DMOFCRY	Discovery agent	N.A.	Investigative	[36]
QUIPAZINE	DMPY6IG	Discovery agent	N.A.	Investigative	[36]
MESULERGINE	DMKGWAH	Discovery agent	N.A.	Investigative	[37]
bilobalide	DM09Z35	Discovery agent	N.A.	Investigative	[38]
2-(4-Methyl-piperazin-1-yl)-quinoline	DMB8OY6	Discovery agent	N.A.	Investigative	[36]
BRL-24682	DMSB4EW	Discovery agent	N.A.	Investigative	[39]
6-(4-Methyl-piperazin-1-yl)-phenanthridine	DM1HAWR	Discovery agent	N.A.	Investigative	[36]
trichloroethanol	DMNALMF	Discovery agent	N.A.	Investigative	[40]
1-phenylbiguanide	DMA4XGL	Discovery agent	N.A.	Investigative	[41]

Drug(s) Targeting 5-HT 3A receptor (HTR3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dolasetron	DMMG26Z	Nausea	MD90	Approved	[42]
Alosetron	DML2A03	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[43]
Tropisetron	DMNSJ7V	Fibromyalgia	MG30.01	Approved	[44]
Palonosetron	DMBHMOX	Nausea	MD90	Approved	[45]
Levetiracetam	DMTGDN8	Epilepsy	8A60-8A68	Approved	[44]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[46]
Cilansetron	DMP0NGX	Irritable bowel syndrome	DD91.0	Phase 3	[47]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[35]
Norcisapride	DMJSKUI	Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 2	[48]
YM-114	DML2IXO	Nausea	MD90	Discontinued in Phase 2	[49]

Drug(s) Targeting 5-HT 1F receptor (HTR1F)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[50]
Lasmiditan	DMXLVDT	Migraine	8A80	Approved	[51]
LY-334370	DM43O9N	Migraine	8A80	Phase 2	[52]
5-CT	DM260KD	Discovery agent	N.A.	Investigative	[50]
TFMPP	DMAC8TP	Discovery agent	N.A.	Investigative	[3]
1-naphthylpiperazine	DM6BIWK	Discovery agent	N.A.	Investigative	[50]
BRL-15572	DMM61Y2	Discovery agent	N.A.	Investigative	[53]
alpha-methyl-5-HT	DMCAYXF	Discovery agent	N.A.	Investigative	[3]
WAY-466	DMMOH51	Discovery agent	N.A.	Investigative	[54]
[125I]LSD	DMP69QG	Discovery agent	N.A.	Investigative	[55]

Drug(s) Targeting 5-HT 1E receptor (HTR1E)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[56]
5-CT	DM260KD	Discovery agent	N.A.	Investigative	[56]
TFMPP	DMAC8TP	Discovery agent	N.A.	Investigative	[56]
1-naphthylpiperazine	DM6BIWK	Discovery agent	N.A.	Investigative	[56]
BRL-15572	DMM61Y2	Discovery agent	N.A.	Investigative	[53]
alpha-methyl-5-HT	DMCAYXF	Discovery agent	N.A.	Investigative	[56]
m-chlorophenylpiperazine	DMM1J2D	Discovery agent	N.A.	Investigative	[56]
EDMT	DMS3AXK	Discovery agent	N.A.	Investigative	[57]
9-OH-risperidone	DMGORXQ	Discovery agent	N.A.	Investigative	[58]
[3H]5-HT	DMYJXV7	Discovery agent	N.A.	Investigative	[59]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1B receptor (HTR1B)	TTK8CXU	5HT1B_HUMAN	Agonist	[1]
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Agonist	[2]
5-HT 1E receptor (HTR1E)	TTCPG9S	5HT1E_HUMAN	Agonist	[3]
5-HT 1F receptor (HTR1F)	TT0MI3F	5HT1F_HUMAN	Agonist	[3]
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Agonist	[4]
5-HT 3A receptor (HTR3A)	TTPC4TU	5HT3A_HUMAN	Agonist	[5]
5-HT 3B receptor (HTR3B)	TTR6K75	5HT3B_HUMAN	Agonist	[6]
5-HT 6 receptor (HTR6)	TTJS8PY	5HT6R_HUMAN	Agonist	[7]

References

• [1] Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4.
• [2] Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996 Dec;50(6):1567-80.
• [3] Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12.
• [4] Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26.
• [5] Pharmacological profile of YM-31636, a novel 5-HT3 receptor agonist, in vitro. Eur J Pharmacol. 2000 Dec 8;409(2):195-201.
• [6] The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999 Jan 28;397(6717):359-63.
• [7] Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacology. 1997 Apr-May;36(4-5):713-20.
• [8] Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
• [11] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [12] Company report (NeurAxon)
• [13] 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
• [14] Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
• [15] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [16] An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
• [17] Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
• [18] Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [20] Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
• [21] 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
• [22] Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
• [23] Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
• [24] The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
• [25] PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
• [26] Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
• [27] Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
• [28] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [29] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [30] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [31] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [32] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [33] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [34] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [35] Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
• [36] Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
• [37] Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8.
• [38] Ginkgolide B and bilobalide block the pore of the 5-HT eceptor at a location that overlaps the picrotoxin binding site. Neuropharmacology. 2011 Feb-Mar;60(2-3):488-95.
• [39] Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
• [40] Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res Mol Brain Res. 2005 Dec 14;142(2):146-50.
• [41] Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
• [42] Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
• [43] Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
• [44] Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
• [45] Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
• [46] Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
• [47] Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
• [48] mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
• [49] Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
• [50] Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76.
• [51] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [52] Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001 Oct 13;358(9289):1230-4.
• [53] SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
• [54] Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
• [55] Isolation of a mouse "5HT1E-like" serotonin receptor expressed predominantly in hippocampus. J Biol Chem. 1992 Oct 5;267(28):19761-4.
• [56] Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39.
• [57] 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
• [58] Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.
• [59] Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5517-21.